National Academies Press: OpenBook
« Previous: 5. Conclusions and Recommendations
Suggested Citation:"References." Institute of Medicine. 1996. Xenotransplantation: Science, Ethics, and Public Policy. Washington, DC: The National Academies Press. doi: 10.17226/5365.
×

References

Allan, J.S. 1995a. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Allan, J.S. 1995b. Xenograft transplantation and the infectious disease conundrum. ILAR J. 37(1):37-48.

American Medical Association (AMA), Council on Ethical and Judicial Affairs. 1995. The use of anencephalic neonates as organ donors. JAMA 273:1614-1618.

Arnold, R. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.


Bach, Fritz H., Simon C. Robson, Christiane Ferran, Hans Winkler, Maria T. Millan, Karl M. Tuhlmeier, Bernard Vanhove, Martin L. Blakely, William J. Van der Werf, Erhard Hofer, Rainer de Martin, and Wayne M. Hancock. 1994. Endothelial cell activation and thromboregulation during xenograft rejection. Immunol. Rev. 141:5-30.

Bach, Fritz H., Simon C. Robson, Hans Winkler, Christiane Ferran, Karl Stuhlmeier, Christopher Wrighton, and Wayne W. Hancock. 1995. Barriers to xenotransplantation. Nature Med. 1:869-873.

Bach, F.H., M.A. Turman, G.M. Vercellotti, J.L. Platt, and A.P. Dalmasso. 1991. Accommodation: A working paradigm for progressing toward discordant xenografting. Transplant. Proc. 23:205-208.

Bevilacqua, M.P., J.S. Pober, G.R. Majeau, R.S. Cotran, and M.A. Gimbrone, Jr. 1984. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J. Exp. Med. 160:618-623.

Suggested Citation:"References." Institute of Medicine. 1996. Xenotransplantation: Science, Ethics, and Public Policy. Washington, DC: The National Academies Press. doi: 10.17226/5365.
×

Bowman, J.E. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Caplan, A.L. 1992. Is xenografting morally wrong? Transplant. Proc. 24(2):722-727.

Chapman, L.E. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Chapman, L.E., T.M. Folks, D.R. Salomon, A.P. Patterson, T.E. Eggerman, and P.D. Noguchi. 1995. Xenotransplantation and xenogeneic infections. N. Engl. J. Med. 333(22):1498-1501.

Cooper, D.K.C. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Cooper, D.K.C., E. Koren, and R. Oriol. 1994. Oligosaccharides and discordant xenotransplantation. Immunol. Rev. 141:31-58.


Dalmasso, A.P., G.M. Vercellotti, J.L. Platt, and F.H. Bach. 1991. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection. Transplantation 52:530-533.

Dresser, R. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.


Evans, R.W. 1989. Money matters: Should ability to pay ever be a consideration in gaining access to transplantation? Transplant. Proc. 21:3419-3423.

Evans, R.W. 1993. Organ transplantation and the inevitable debate as to what constitutes a basic health care benefit. Pp. 359-391 in P.I. Terasaki and J.M. Cecka (Eds.), Clinical Transplantation 1993. Los Angeles: UCLA Tissue Typing Laboratory, UCLA School of Medicine.

Evans, R.W. 1995a. Liver transplantation in a managed care environment. Liver Trans. Surg. 1:61-75.

Evans, R.W. 1995b. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Evans, R.W., C.R. Blagg, and F. Bryan. 1981. Implications for health care policy: A social and demographic profile of hemodialysis patients in the U.S. JAMA 245:487-491.


Faustman, D. 1995. Strategy for successful xenograft survival: Designer modification of cells, tissues and organs. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Faustman, D., and C. Coe. 1991. Prevention of xenograft rejection by masking donor HLA class 1 antigens. Science 252:1700-1702.

Suggested Citation:"References." Institute of Medicine. 1996. Xenotransplantation: Science, Ethics, and Public Policy. Washington, DC: The National Academies Press. doi: 10.17226/5365.
×

Fodor, W.L., B.L. Williams, L.A. Matis, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc. Natl. Acad. Sci. USA 91:11153-11157.

Fox, R.C. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Fox, R.C., and J.P. Swazey. 1992. Spare Parts: Organ Replacement in American Society. New York: Oxford University Press.

Gaines, B.A., and Suzanne T. Ildstad. 1995. Xenoreactivity, chimerism, and tolerance. Pp. 172-188 in Suzanne T. Ildstad (Ed.), Chimerism and Tolerance. R.G. Lanes Company Publishers.

Gianelli, D.M. 1995. Ethics council reverses stand on anencephalic organ donors. Am. Med. News 38(48):3-8.


Hammer, C. 1989. Evolutionary considerations in xenotransplantation. Pp. 115-123 in Mark A. Hardy (Ed.), Xenograft, Vol. 25. Congress Series 880.

Hancock, W.W. 1984. Analysis of intragraft effector mechanisms associated with human renal allograft rejection: Immunohistological studies using monoclonal antibodies. Immunol. Rev. 77:61-84.


Ildstad, S. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Institute of Medicine (IOM). 1991. Kidney Failure and the Federal Government. Washington, DC: National Academy Press.

Institute of Medicine (IOM). 1992. Emerging Infections: Microbial Threats to Health in the United States. Washington DC: National Academy Press.


Kahan B.D. 1995. Presentation to the IOM Conference on Xenograft Transplanation: Science, Ethics, and Public Policy. June 25-27.

Kahan, B.D., and R. Ghobrial. 1994. Immunosuppressive agents. Surg. Clin. North Am. 74:1029-1054.

Kaufman, C.L., Y.L. Colson, S.M. Wren, et al. 1994. Phenotypic characterizations of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 84(8):2436-2445.

Kaufman, C., Barbara A. Gaines, and Suzanne T. Ildstad. 1995. Xenotransplantation. Ann. Rev. Immunol. 13:339-367.

Keeling, M. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Kessler, D.A., J.P. Siegel, P.D. Noguchi, et al. 1993. Regulation of somatic cell therapy and gene therapy by the Food and Drug Administration. N. Engl. J. Med. 329:1169-1173.

Suggested Citation:"References." Institute of Medicine. 1996. Xenotransplantation: Science, Ethics, and Public Policy. Washington, DC: The National Academies Press. doi: 10.17226/5365.
×

Khabbaz, R.F., W. Heneine, J.R. George, et al. 1994. Brief report: Infection of a laboratory worker with simian immunodeficiency virus. N. Engl. J. Med. 330:172-177.

Koller, B. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

McCarthy, C.R. 1995. Ethical aspects of animal to human xenografts. ILAR J. 37(1):3-8.

McKenzie, J.F.C., S. Cohney, H.A. Vaughan, N. Osman, J. Atkin, E. Elliott, W.L. Fodor, M.A. Gallop, K.R. Oldenburg, D. Burton, and M.S. Sandrin. 1995. Overcoming the anti-Gala(1-3)Gal reaction in xenotransplantation. Xenotransplantation 3:86-89.

Menzel, P.T. 1988. Some ethical costs of rationing. Pp. 155-164 in Deborah Mattheiu (Ed.), Organ Substitution Technology. Boulder, CO: Westview Press.

Menzel, P.T. 1992. Scarce dollars for saving lives: The case of heart and liver transplants. Law, Med., and Health Care 20:57-66.

Menzel, P.T. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Merrill, R.A. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Michaels, M. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Michaels, M.G., and R.L. Simmons. 1994. Xenotransplant-associated zoonoses. Strategies for Prevention. Transplantation 57:1-7.

Morse, S. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Moskop, J.C. 1991. Ability to pay and access to transplantation. Pp. 433-436 in W. Land and J.G. Dossetor (Eds.), Organ Replacement Therapy: Ethics, Justice, Commerce. Berlin: Springer-Verlag.


National Research Council. 1989. Improving Risk Perception and Communication. Washington, DC: National Academy Press.


Persing, D. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Platt, J.L. 1994. A perspective on xenograft rejection and accommodation. Pp. 127-149 in Goran Moller (Ed.), Immunological Reviews, Vol. 141.

Platt, J.L. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Suggested Citation:"References." Institute of Medicine. 1996. Xenotransplantation: Science, Ethics, and Public Policy. Washington, DC: The National Academies Press. doi: 10.17226/5365.
×

Platt, J.L., G.M. Vercellotti, B. Lindman, T.R. Oegema, Jr., F.H. Bach, and A.P. Dalmasso. 1990. Release of heparan sulfate from endothelial cells: Implications for pathogenesis of hyperacute rejection. J. Exp. Med. 171:1363-368.

Pober, J.S., and M.A. Gimbrone, Jr. 1982. Expression of Ia-like antigens by human vascular endothelial cells is inducible in vitro: Demonstration by monoclonal antibody binding and immunoprecipitation. Proc. Natl. Acad. Sci. USA 53:1851-1854.

Ricordi, C. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy, June 25-27, 1995.

Rothman, D. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.


Scharp, D., C.J. Swanson, B.J. Olack, et al. 1994. Protection of encapsulated human islets implanted without immunosuppression in patients with type I or type II diabetes and in nondiabetic control subjects. Diabetes 43:1167-1170.

Siminoff, L., R.M. Arnold, A.L. Caplan, B.A. Virnig, and D.L. Seltzer. 1995. Public policy governing organ and tissue procurement in the United States. Ann. Intern. Med. 123:10-17.

Spital, A. 1995. Mandated choice: A plan to increase public commitment to organ donation. JAMA 273(6):504-506.

Squinto, S., and W.L. Fodor. 1995. Transgenic swine engineered to be resistant to the humoral immune system of primates. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Starzl, T.E. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Starzl, T.E., A.J Demetris, M. Trucco, et al. 1993. Cell migration and chimerism after whole-organ transplantation: The basis of graft acceptance. Hepatology 17(6):1127-1152.

Swindle, M. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.


Terasaki, P.I., J.M. Cecka, D.W. Gjertson, and S. Takemoto. 1995. High survival rates of kidney transplants from spousal and living unrelated donors. N. Engl. J. Med. 333(6):333-336.


United Network for Organ Sharing (UNOS). 1994. Annual Report of the U.S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network--Transplant Data: 1988-1994. Richmond, VA: UNOS.

U.S. Bureau of Labor Statistics (BLS). 1994. Employee Benefits in Medium and Large Private Establishments, 1993. Bulletin 2456. Washington, D.C.: U.S. Department of Labor.

Suggested Citation:"References." Institute of Medicine. 1996. Xenotransplantation: Science, Ethics, and Public Policy. Washington, DC: The National Academies Press. doi: 10.17226/5365.
×

U.S. Food and Drug Administration (FDA). 1993. Application of current statutory authorities to human somatic cell therapy products and gene therapy products. Federal Register Notice, October 14.

Walters, J. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Suggested Citation:"References." Institute of Medicine. 1996. Xenotransplantation: Science, Ethics, and Public Policy. Washington, DC: The National Academies Press. doi: 10.17226/5365.
×
Page 97
Suggested Citation:"References." Institute of Medicine. 1996. Xenotransplantation: Science, Ethics, and Public Policy. Washington, DC: The National Academies Press. doi: 10.17226/5365.
×
Page 98
Suggested Citation:"References." Institute of Medicine. 1996. Xenotransplantation: Science, Ethics, and Public Policy. Washington, DC: The National Academies Press. doi: 10.17226/5365.
×
Page 99
Suggested Citation:"References." Institute of Medicine. 1996. Xenotransplantation: Science, Ethics, and Public Policy. Washington, DC: The National Academies Press. doi: 10.17226/5365.
×
Page 100
Suggested Citation:"References." Institute of Medicine. 1996. Xenotransplantation: Science, Ethics, and Public Policy. Washington, DC: The National Academies Press. doi: 10.17226/5365.
×
Page 101
Suggested Citation:"References." Institute of Medicine. 1996. Xenotransplantation: Science, Ethics, and Public Policy. Washington, DC: The National Academies Press. doi: 10.17226/5365.
×
Page 102
Next: Appendix A-Workshop Agenda »
Xenotransplantation: Science, Ethics, and Public Policy Get This Book
×
Buy Paperback | $46.00 Buy Ebook | $36.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Xenotransplantation involves the transplantation of cells, tissues, and whole organs from one species to another. Interest in animal-to-human xenotransplants has been spurred by the continuing shortage of donated human organs and by advances in knowledge concerning the biology of organ and tissue rejection. The scientific advances and promise, however, raise complex questions that must be addressed.

This book considers the scientific and medical feasibility of xenotransplantation and explores the ethical and public policy issues surrounding the possibility of renewed clinical trials. The volume focuses on the science base of xenotransplantation, public health risks of infectious disease transmission, and ethical and public policy issues, including the views of patients and their families.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!